C3G
5
Pipeline Programs
1
Companies
4
Clinical Trials
2
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
2
Early DiscoveryClinical DevelopmentMarket
On Market (2)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
Apellis PharmaceuticalsAustralia - Hawthorn East
4 programs1
2
1
PegcetacoplanPhase 31 trial
PegcetacoplanPhase 31 trial
PegcetacoplanPhase 21 trial
PegcetacoplanN/A1 trial
Active Trials
NCT04729062Approved For Marketing
+1 more trialsTrial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
Apellis PharmaceuticalsPegcetacoplan
Apellis PharmaceuticalsPegcetacoplan
Apellis PharmaceuticalsPegcetacoplan
Clinical Trials (4)
Total enrollment: 237 patients across 4 trials
An Open-Label, Nonrandomized, Multicenter Extension Study to Evaluate the Long-term Safety and Efficacy of Pegcetacoplan in Participants With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Start: May 2023Est. completion: Jul 2027100 patients
Phase 3Active Not Recruiting
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
Start: Nov 2021Est. completion: Jan 2025124 patients
Phase 3Completed
Study Assessing the Safety and Efficacy of Pegcetacoplan in Post-Transplant Recurrence of C3G or IC-MPGN
Start: Sep 2021Est. completion: Jan 202613 patients
Phase 2Active Not Recruiting
C3G/Primary IC-MPGN EAP
N/AApproved For Marketing
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space